Immunic (IMUX) Capital Expenditures (2013 - 2026)
Immunic (IMUX) posted Capital Expenditures of $2000.0 for Q1 2026, down 81.82% sequentially from $11000.0 in Q4 2025, and down 95.74% YoY from $47000.0 in Q1 2025.
Immunic (IMUX) Capital Expenditures (2013 - 2026) Analysis & Trends
Immunic has reported Capital Expenditures for 14 years, with the latest figure at $2000.0 in Q1 2026.
- Quarterly Capital Expenditures fell 95.74% year-over-year to $2000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $116000.0 (down 58.57% YoY) and the FY2025 annual result came in at $161000.0, down 39.02% from the prior year.
- Capital Expenditures fell to $2000.0 in Q1 2026 per IMUX's latest filing, from $11000.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $180000.0 in Q2 2024 and troughed at -$1000.0 in Q4 2022.
- A 5-year average of $51352.9 and a median of $36000.0 in 2025 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2022 and 2023: Capital Expenditures sank 105.26% in 2022, then jumped 16600.0% in 2023.
- Over 5 years, Capital Expenditures stood at -$1000.0 in 2022, then surged by 16600.0% to $165000.0 in 2023, then plunged by 98.18% to $3000.0 in 2024, then surged by 266.67% to $11000.0 in 2025, then slumped by 81.82% to $2000.0 in 2026.
- According to Business Quant data, Capital Expenditures over the past three periods registered $2000.0, $11000.0, and $67000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Immunic | 682.77 Mn | 682.77 Mn | - | 249,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 249,000.00 |
| Jun 30, 2026 | 249,000.00 |
| Mar 31, 2026 | 2,000.00 |
| Mar 31, 2026 | 2,000.00 |
| Dec 31, 2025 | 11,000.00 |
| Dec 31, 2025 | 11,000.00 |
| Sep 30, 2025 | 67,000.00 |
| Sep 30, 2025 | 67,000.00 |
| Jun 30, 2025 | 36,000.00 |
| Jun 30, 2025 | 36,000.00 |
| Mar 31, 2025 | 47,000.00 |
| Mar 31, 2025 | 47,000.00 |
| Dec 31, 2024 | 3,000.00 |
| Dec 31, 2024 | 3,000.00 |
| Sep 30, 2024 | 50,000.00 |
| Sep 30, 2024 | 50,000.00 |
| Jun 30, 2024 | 180,000.00 |
| Jun 30, 2024 | 180,000.00 |
| Mar 31, 2024 | 31,000.00 |
| Mar 31, 2024 | 31,000.00 |